loading page

Food Allergy Treatment Value: Child Caregiver and Patient Perspectives
  • +2
  • Moaz Abdelwadoud,
  • Sanaz Eftekhari,
  • Hannah Jaffee,
  • Melanie Carver,
  • T. Mattingly II
Moaz Abdelwadoud
University of Maryland Baltimore
Author Profile
Sanaz Eftekhari
Asthma and Allergy Foundation of America
Author Profile
Hannah Jaffee
Asthma and Allergy Foundation of America
Author Profile
Melanie Carver
Asthma and Allergy Foundation of America
Author Profile
T. Mattingly II
University of Maryland Baltimore
Author Profile

Abstract

Background: Food allergy is a major health problem that significantly impacts quality of life (QoL). There is growing focus to evaluate food allergy related QoL and treatment value beyond the clinical effectiveness perspective by engaging patients and caregivers. We aimed to identify and prioritize outcomes important to food allergy parents of children and patients allergic to milk, egg, and/or peanut, to guide comparative effectiveness research (CER) that focuses on evaluating food allergy treatment decisions. Methods: We conducted a modified 3-round Delphi study to identify and derive consensus on priority treatment outcomes for parents of children and adult patients with diagnosed allergies to at least one of three major allergenic foods (milk, egg, and peanut) from across the United States. Results: Round 1 yielded 44 statements for round 2, and 39 statements reached the agreement level for round 3 ranking. Statements were organized under 4 sections: 1) food allergy problems, 2) treatment experiences, 3) important treatment outcomes, and 4) value of different treatment options. Conclusion: Food allergy parents and patients face several social, psychological, medical, healthcare, financial, food selection, and awareness challenges. The areas of consensus on important treatment outcomes revealed shared priority for reducing the risk of potentially fatal allergic reactions and having reliable treatments. The most valued treatment options reflect hope for permanent cure and fear of serious allergic reactions.

Peer review status:ACCEPTED

22 Dec 2020Submitted to Pediatric Allergy and Immunology
24 Dec 2020Reviewer(s) Assigned
21 Jan 2021Review(s) Completed, Editorial Evaluation Pending
25 Jan 2021Editorial Decision: Revise Major
27 Jan 20211st Revision Received
27 Jan 2021Review(s) Completed, Editorial Evaluation Pending
28 Jan 2021Reviewer(s) Assigned
02 Feb 2021Editorial Decision: Accept